KRAS mutant inhibitor ALTA3263

An orally bioavailable non-covalent dual ON/OFF state inhibitor of multiple oncogenic KRAS mutant forms, including KRAS G12V, G12D and G12C, with potential antineoplastic activity. Upon oral administration, KRAS mutant inhibitor ALTA3263 selectively targets and binds to KRAS, thereby inhibiting KRAS-dependent signaling. This inhibits the growth and survival of KRAS-overexpressing and mutated tumor cells. KRAS, a member of the RAS family of oncogenes, plays an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.